Caracterización clínica, epidemiológica y microbiológica de bacteriemias producidas por enterobacterias resistentes a carbapenems en un hospital universitario de Córdoba, Argentina / Clinical, epidemiological and microbiological characterization of bacteremia produced by carbapenem-resistant enterobacteria in a university hospital in Córdoba, Argentina

Resumen Introducción: Las enterobacterias son una causa principal de infecciones del torrente sanguíneo y su resistencia antimicrobiana se encuentra en aumento. Esto lleva a un incremento de la morbilidad-mortalidad y de los costos en la salud pública. Las enterobacterias resistentes a carbapenems representan un grave desafío a nivel global ya que existen escasas opciones terapéuticas disponibles. Objetivo: Caracterización clínico/microbiológica de las bacteriemias resistentes a carbapenémicos observadas en un período de 4 años. Material y Método: Estudio retrospectivo, observacional y descriptivo, sobre las bacteriemias por enterobacterias resistentes y sensibles a carbapenems. Resultados: Se analizó un total de 84 pacientes con bacteriemia por enterobacterias resistentes y sensibles a carbapenems. Entre las resistentes, observamos una mayor proporción de: tratamiento antimicrobiano previo, hospitalización en unidad de terapia intensiva (UTI), inicio de la bacteriemia en UTI y antecedentes de β-lactamasas de espectro extendido. Además, se detectó un amplio predominio de Klebsiella pneumoniae productor de KPC y una mortalidad atribuible de 52,4%. Discusión: El estudio posibilitó profundizar el conocimiento de una enfermedad emergente de elevada mortalidad, en vistas al diseño y aplicación de estrategias de control de infecciones y de esquemas de tratamiento efectivos adaptados a la epidemiologia local.

Abstract Background: Enterobacteriaceae are a major cause of bloodstream infections and their antimicrobial resistance continues to increase. This leads to higher morbidity-mortality rates and public health costs. Carbapenem-resistant Enterobacteriaceae represent a serious challenge globally, since there are few therapeutic options available. Aim: Clinical/microbiological characterization of the carbapenem-resistant bacteremia observed over a period of 4 years. Methods: Retrospective, observational and descriptive study about bacteremia caused by carbapenem-resistant and susceptible Enterobacteriaceae. Results: A total of 84 patients with bacteremia including carbapenem-resistant and susceptible Enterobacteriaceae were analyzed. We found that patients infected with carbapenem-resistant strains presented a higher proportion of: previous antibiotic treatment, hospitalization in intensive care unit (ICU), onset of the bacteremia during hospitalization in ICU and previous infection with extended-spectrum-beta-lactamase producing Enterobacteriaceae. Additionally, we observed a predominance of KPC-producing Klebsiella pneumoniae and an attributable mortality rate of 52.4%. Discussion: This study allowed for a better understanding of an emerging problem with high mortality, which in turn is useful for the design and adoption of infection control strategies and effective treatment regimens adapted to our local epidemiology.

Evaluación de la elución de sensidiscos para la determinación de susceptibilidad a colistín en bacilos gramnegativos multi-resistentes / Evaluation of sensi-disk elution for colistin susceptibility determination in multidrug resistant gramnegative bacilli

Resumen Utilizando cepas clínicas de bacilos gramnegativos multi-resistentes (MDR), comparamos las CIM obtenidas de la microdilución en caldo, el método de referencia y el método de elución de sensidiscos. Encontramos que, con la excepción de A. baumannii, los resultados fueron muy similares. El método de elución de sensidiscos podría ser una buena alternativa y confiable para la determinación de la resistencia a colistín.

Abstract Using clinical strains of multidrug resistant (MDR) Gram negative bacilli, we compared MICs obtained from both broth microdilution, the reference method, and sensi-disk elution method. We found that, with A. baumannii exception, results were very similar. Sensi-disk elution method could be a good and reliable alternative for colistin resistance determination.

Evaluación de la sensibilidad de cepas de Pseudomonas aeruginosa multi-resistentes frente a ceftolozano/tazobactam / Evaluation of susceptibility of multidrug-resistant Pseudomonas aeruginosa strains against ceftolozane/tazobactam

Resumen Introducción: Pseudomonas aeruginosa es un patógeno oportunista asociado a alta morbi-mortalidad. Para cepas multi-resistentes (MDR), ceftolozano/tazobactam (CTZ) se ha autorizado por la Agencia Europea del Medicamento (EMA) para infecciones del tracto urinario complicadas, pielonefritis aguda e infecciones intra-abdominales complicadas. Objetivo: Determinar la sensibilidad a CTZ de P. aeruginosa MDR en muestras clínicas aisladas en el Hospital Universitario Puerto Real. Material y Métodos: Se estudió la sensibilidad según criterios EUCAST a CTZ de cepas de P. aeruginosa MDR, entre enero de 2015 y agosto de 2017. Los criterios de multi-resistencia fueron definidos por el Centers for Disease Control and Prevention. La sensibilidad antimicrobiana se obtuvo mediante sistema MicroScan® (Beckman Coulter). La sensibilidad a CTZ se determinó mediante tiras de gradiente (Liofilchem®, Werfen). Resultados: De 1253 cepas, 7% fueron MDR. Se estudió la sensibilidad de 78 cepas de P. aeruginosa MDR, de las cuales cinco (6,4%) resultaron resistentes a CTZ según criterios EUCAST. Conclusiones: En nuestro medio la resistencia in vitro a CTZ en cepas de P. aeruginosa MDR es aproximadamente 6%; CTZ es una opción de tratamiento de infecciones por cepas de P. aeruginosa MDR cuando no exista otra alternativa y se haya comprobado su sensibilidad in vitro.

Background: Pseudomonas aeruginosa is an opportunistic pathogen associated with high morbidity and mortality. For multidrug-resistant strains (MDR), ceftolozane/tazobactam (CTZ) has been authorized by the European Medicines Agency (EMA) for complicated urinary tract infections, acute pyelonephritis, and complicated intraabdominal infections. Aim: To determine the susceptibility to CTZ of P. aeruginosa MDR in isolated clinical samples at the University Hospital Puerto Real. Methods: The susceptibility according to the EUCAST to CTZ criteria of strains of P. aeruginosa MDR, between January 2015 and August 2017 has been studied. The multiresistance criteria were those defined by the Centers for Disease Control and Prevention. The antibiotic susceptibility was obtained by automated MicroScan® system (Beckman Coulter). Susceptibility to CTZ was determined using gradient strips (Liofilchem®, Werfen). Results: Of 1253 strains isolated, 7% presented MDR. We studied the susceptibility of a total of 78 strains of MDR P. aeruginosa, of which 5 (6.4%) were resistant to CTZ according to the EUCAST criteria. Conclusions: In our environment, the in vitro resistance to CTZ in MDR P. aeruginosa strains is approximately 6%. CTZ is an option for the treatment of infections by MDR P. aeruginosa when there is no other alternative and its in-vitro susceptibility has been proven.

El desafio en la dosificación de colistin: actualización de las recomendaciones disponibles / The challenge in colistin dosing: updating available recommendations

Resumen Las polimixinas están disponibles desde la década de los 60; sin embargo, debido a sus efectos adversos su uso ha sido reservado para el tratamiento de infecciones provocadas por bacterias multi-resistentes. El aumento en la experiencia clínica adquirida en los últimos años y la literatura médica publicada han planteado dudas respecto de la información entregada del producto, poniendo en manifiesto la necesidad de actualizar las recomendaciones posológicas, su farmacocinética y la información farmacocinética/farmacodinámica. Además, las diferencias en cuanto a concentración y dosis entre los distintos productos del colistín pueden dar lugar a errores de indicación/administración y suponer un riesgo para los pacientes. El año 2013, la Agencia Europea de Medicamento (EMA) encargó al Comité de Productos Medicinales para uso Humano (CHPM) la revisión de los datos disponibles y que formulara recomendaciones actualizadas del uso de colistín. Dicho procedimiento arrojó un primer informe en 2014. Esta revisión destaca los aspectos críticos de seguridad y eficacia, revisa los recientes avances farmacocinéticos y de estabilidad, las formas farmacéuticas disponibles en Chile, proporcionando los esquemas actualmente recomendados por agencias sanitarias y expertos en el tema para distintos escenarios clínicos.

Polymyxins have been available since the 1960s, however, because of their adverse effects, their use has been reserved for the treatment of infections caused by multiresistant bacteria. The increase in the clinical experience acquired in recent years and the published medical literature have raised doubts about the information provided by the product, indicating the need to update dosage recommendations, pharmacokinetics and pharmacokinetic/pharmacodynamic information (PK/PD). In addition, differences in concentration and dose between the different products of colistin may lead to errors of indication/administration and pose a risk to patients. In 2013, the European Medicines Agency (EMA) commissioned the Committee for Medicinal Products for Human Use (CHPM) to review available data and to make updated recommendations on the use of colistin. This procedure yielded a first report in 2014. This review highlights critical safety and efficacy aspects, reviews the recent pharmacokinetic and stability advances, the available pharmaceutical forms in Chile, providing the schemes currently recommended by health care agencies and experts in the field.

Factores de riesgo para la adquisición y características microbiológicas de las bacteriemias por Acinetobacter baumannii multi-resistente en pediatría: Estudio de casos y controles / Microbiological features and risk factors for acquiring multidrug-resistant Acinetobacter baumannii bacteremia in pediatric patients: Case-control study

Background: Multidrug-resistant Acinetobacter baumannii (MAB) is an important nosocomial pathogen. Objectives: To analyze the risk factors for acquiring MAB, and the clinical and microbiological characteristics of MAB bacteremia (MABB) in children. Materials and Methods: Control-case study 2005-2008. Demographic and clinical data from all MABB and from non-multiresistant gram-negative bacteremias were recorded. Identification at species level, antimicrobial susceptibility tests, time-kill studies and clonally relationships were performed. Stata 8.0 was used for data analysis. Results: A total of 50 MABB and 100 controls were included. Ninety four percent of patients acquired MAB in ICU and the 88% had underlying diseases. All patients had invasive procedures previous to MABB. The median of hospitalization stay previous to MABB was different in cases than in controls (16 vs 7 days, p < 0.001). Five clones were detected among the MABB. Time-killing curves showed bactericidal activity of ampicillin/sulbactam plus gentamicin and polymixin B. Three patients with MAB died. In a multivariate analysis final predictors of MABB were: previous use of broad-spectrum antibiotics [OR: 7,0; IC 95% 1,93-25,0; p: 0,003] and mechanical ventilation [OR: 4,19; IC 95% 1,66-10,0; p: 0,002]. Conclusions: MABB were detected in patients with underlying conditions, invasive procedures and prolonged hospitalization. Predictors of MABB were mechanical previous use of broad-spectrum antibiotics and mechanical ventilation.

Introducción: Acinetobacter baumannii multi-resistente (ABM) es un patógeno intrahospitalario de importancia. Objetivos: Analizar factores de riesgo de adquisición y características clínicas y microbiológicas de las bacteriemias por ABM (BABM) en pediatría. Métodos: Estudio de casos y controles período 2005-2008. Se incluyeron variables demográficas y clínicas de pacientes con BABM y por otros bacilos gramnegativos no ABM. Se realizaron pruebas para identificación de especie, susceptibilidad antimicrobiana y detección feno-genotípica de mecanismos de resistencia, sinergia y clonalidad. Análisis estadístico: Stata 8.0. Resultados: Se incluyeron 50 BABM y 100 controles. El 94% de los pacientes adquirieron la BABM en UCI y 88% tenía patologías subyacentes. La mediana de días de internación previa a la bacteriemia fue mayor en los casos (16 vs 7 días, p < 0,001). Se detectaron cinco clones de ABM. Se encontró efecto bactericida in vitro con polimixina B y con ampicilina/sulbactam+gentamicina. Tres casos fallecieron. Análisis multivariado: predictores finales de BABM fueron: antimicrobiano previo de amplio espectro [OR: 7,0; IC 95% 1,93-25,0; p: 0,003] y asistencia respiratoria mecánica (ARM) [OR: 4,19; IC 95% 1,66-10,0; p: 0,002]. Conclusiones: Las BABM fueron detectadas en pacientes con enfermedad subyacente, con procedimientos invasores previos e internación prolongada. Fueron predictores de BABM el tratamiento antimicrobiano de amplio espectro y ARM previa.

Factores de riesgo para infección por Pseudomonas aeruginosa multi-resistente en un hospital de alta complejidad / Risk factors for multidrug-resistant Pseudomonas aeruginosa infection, in a tertiary hospital in Colombia

Introduction: multi-resistant Pseudomonas aeruginosa (MR) is frequently associated with healthcare infections. Its epidemiology is complex and few studies help to understand it. A study about risk factors associated with this type of bacteria is needed. Objective: To determine risk factors associated with MR P. aeruginosa infection in hospitalized patients from the Hospital Universitario San Vicente Foundation-Medellin. Materials and Methods: case-control study to identify risk factors associated with infection by MR P. aeruginosa. Results: 140 patients were included, 70 in each group. Bivariate analysis found association with previous use of carbapenems (OR 3.12 - IC 1.21 to 8.03, p = 0.02), aminoglycosides (OR 5.09 - CI: 1.38 to 18, 77, p = 0.01) and days of stay prior to isolation of the organism (OR 1.03 - CI: 1.01-1.05, p = 0.01). In multivariate analysis MR P. aeruginosa infection was associated with hospital stay (OR 1.03 - IC 1.01 to 1.05), use of aminoglycosides (OR 1.30 to 19.28) and treatment with two or more antimicrobials in the last 30 days (OR 3.09 - CI: 1.26 to 7.58). The risk of developing infection was 3% per day of hospital stay prior to isolation of the agent. Conclusion: Developing MR P. aeruginosa infection was associated with prior use of antimicrobials and prior hospital stay.

Introducción: Pseudomonas aeruginosa multi-resistente (MR) es causa frecuente de infecciones asociadas al cuidado de la salud, su epidemiología es compleja y hay pocos estudios que permiten comprenderla. El estudio de los factores de riesgo asociados a este tipo de bacterias es necesario para la implementación de estrategias de control de las mismas. Objetivo: Determinar factores de riesgo asociados a infección por P. aeruginosa MR en pacientes hospitalizados en el Hospital Universitario de San Vicente Fundación-Medellín. Materiales y Métodos: Estudio analítico con abordaje como casos y controles para determinar factores de riesgo asociados a infección por P. aeruginosa MR. Resultados: Se incluyó un total de 140 pacientes, 70 en cada grupo. En el análisis bivariado se encontró asociación con el uso previo de carbapenémicos (OR 3,12- IC 1,21-8,03; p: 0,02), aminoglucósidos (OR 5,09- IC: 1,38-18,77; p: 0,01) y el tiempo por día de estancia previo al aislamiento (OR 1,03- IC: 1,01-1,05; p: 0,01). En el análisis multivariado hay asociación entre la estancia hospitalaria (OR 1,03- IC 1,01-1,05), el uso de aminoglucósidos (OR 1,30-19,28) y el uso de dos o más antimicrobianos en los últimos 30 días (OR 3,09- IC: 1,26-7,58) con el desarrollo de infecciones por P. aeruginosa MR. El riesgo de desarrollar una infección por esta bacteria fue de 3% por cada día de estancia hospitalaria previo al aislamiento. Conclusión: El desarrollar infección por P. aeruginosa MR se asoció con el uso previo de antimicrobianos y con el tiempo previo de estancia hospitalaria.

Patrones de susceptibilidad antimicrobiana de cepas de Shigella sonnei aisladas durante tres períodos diferentes en la Región Metropolitana, Chile / Antibiotic susceptibility patterns among Shigella sonnei, isolated during three different periods in Región Metropolitana, Chile

Background: Shigella sonnei gastroenteritis improves clinically and microbiologically with antibacterial treatment; however choosing a useful drug is a universal challenge because of in vitro susceptibility of S. sonnei frequently evolves to be resistant. Objective: To evaluate in vitro susceptibility of S. sonnei strains isolated from patients attending at the Chilean Región Metropolitana and to know the evolution that resistant patterns of S. sonnei have experienced. Material: In this study, the antimicrobial susceptibility profile of 277 isolates of Shigella sonnei was compared. The analyzed periods of time were: period I (1995-1997) 85 strains; period II (2004-2006) 92 strains and period III (2008-2009) 100 strains, in Santiago, Chile. The method performed to analyze susceptibility patterns was the disc diffusion (Kirby-Bauer). Results: The strains showed rates of resistance to ampicillin: period I, 85.8%; period II, 53.3%; period III, 100%, trimethoprim/sulfamethoxazole: period I, 50.5%; period, II 46.7%; period III, 100%, chloramphenicol: period I, 36.4%; period II, 12%; period III, 100% and tetracycline: period I, 38.8%; period II, 30.4%; period III, 100%. 98.9% of the strains showed susceptibility to quinolones. Significant differences were observed in patterns of antimicrobial resistance for both individuals and for multidrug resistance (≥ 3 antimicrobials) in the three periods (p < 0.001, χ2 test). Of all resistant strains, 17% were resistant to 1 or 2 antibiotics, while 65.7% showed a pattern of multidrug resistance; 100% of the period III strains presented multidrug resistance. Conclusion: These results showed the temporal resistance dynamics of S. sonnei circulating strains in the Chilean Región Metropolitana. Due to the endemic behavior of shigellosis in Chile, it is urgent to maintain permanent surveillance of antimicrobial resistance profiles to improve both prevention and treatment of shigellosis.

Introducción: La infección entérica producida por Shigella sonnei mejora clínicamente y microbiológicamente con antibioterapia; sin embargo, la elección del antimicrobiano es un problema universal pues la susceptibilidad in vitro de S. sonnei evoluciona frecuentemente hacia la resistencia. Objetivo: Evaluar la susceptibilidad in vitro a antimicrobianos de S. sonnei y conocer la evolución que han experimentado los patrones de resistencia de cepas aisladas de cuadros clínicos en pacientes de la Región Metropolitana, Chile. Material y Métodos: Se comparó el perfil de susceptibilidad a antimicrobianos, de 277 cepas clínicas de S. sonnei aisladas durante tres períodos: período I (1995-1997) 85 cepas; período II (2004-2006) 92 cepas y período III (2008-2009) 100 cepas, en Santiago, Chile. El perfil de susceptibilidad a antimicrobianos se determinó mediante test de difusión en agar. Resultados: Las tasas de resistencia de las cepas en los periodos I, II y III respectivamente fueron: ampicilina: 85,8%; 53,3%; 100%, cotrimoxazol: 50,5%; 46,7%; 100%, cloranfenicol: 36,4%; 12%; 100% y tetraciclina: 38,8%; 30,4%; 100%. El 98,9% de las cepas fue susceptible a quinolonas. Se observó diferencias significativas en los porcentajes de resistencia para antimicrobianos individuales y multi-resistencia (≥ 3 antimicrobianos) en los tres períodos (p < 0,001; Test de χ2). De las cepas resistentes, 17% presentó resistencia a uno ó dos antimicrobianos, 65,7% mostró multi-resistencia antimicrobiana. El 100% de las cepas del período III presentó multi-resistencia. Discusión: Estos resultados evidencian la dinámica temporal de la resistencia en cepas de S. sonnei circulantes en la Región Metropolitana. Dado que en Chile la shigelosis tiene un carácter endémico, es prioritario mantener una vigilancia constante de los perfiles de resistencia a antimicrobianos, para mejorar la prevención y el tratamiento de la shigelosis.

Resistência a β-lactâmicos em Acinetobacter spp isolados de efluente hospitalar no sul do Brasil / Resistance to β-lactams among Acinetobacter spp isolated from hospital sewage in southern Brazil

Acinetobacter spp é um importante patógeno causador de infecções nosocomiais que acomete pacientes imunocomprometidos e capaz de adquirir resistência a antimicrobianos com facilidade. Os esgotos hospitalares são importantes disseminadores de genes de resistência a antimicrobianos para a microbiota ambiental. Neste contexto, 30 cepas de Acinetobacter spp provenientes de efluente de um hospital em Porto Alegre, RS, foram analisados quanto ao perfil de susceptibilidade a β-lactamases, quinolonas e aminoglicosídeos através de antibiograma e testes de triagem para metalo beta-lactamases e β-lactamases de espectro estendido. O perfil encontrado revela cepas multi-resistentes e que mecanismos de resistência como a produção de β-lactamases de espectro estendido e bombas de efluxo podem estar presentes nesses isolados.

Acinetobacter spp is an important pathogen that is responsible for nosocomial infections affecting immunocompromised patients, and it can easily acquire resistance to antimicrobial agents. Hospital sewage is an important means for disseminating genes for resistance to antimicrobial agents, to the microbiota of the environment. Within this context, 30 strains of Acinetobacter spp from the sewage of a hospital in Porto Alegre, Rio Grande do Sul, were analyzed regarding their profile of susceptibility to β-lactams, quinolones and aminoglycosides, by means of an antibiogram and tests to screen for metallo-β-lactamases and extended-spectrum β-lactamases. The profile obtained revealed the presence of multidrug-resistant strains and showed that resistance mechanisms such as the production of extended-spectrum β-lactamases and efflux pumps may be present in these strains.

Microrganismos patogênicos, celularidade e resíduos de antimicrobianos no leite bovino produzido no sistema orgânico

In last years increase the importance of milk quality and conditions of bovine milking. Simultaneously, increase the interest about organic milk and derivates. The aim of present study was investigate the milk pathogens, sensitivity and multiple drug resistance of isolates, somatic cell count and residues of drugs in milk, from cattle with and without mastitis, come from four little organic dairy farms in State of São Paulo, Brazil. Were used 148 cattle on the middle period of lactation. From these, two showed clinical mastitis, 72 subclinical mastitis and 74 without signs of mammary inflammation (controls). Staphylococcusaureus (25.7%), Streptococcus spp. (21.4%), Corynebacterium bovis (12.9%), Streptococcus agalactiae (4.3%) and Staphylococcus spp. (4.3%) were the more-frequent microorganisms isolated from animals with mastitis. Aspergillus spp. was isolated from one animal. Ceftiofur (95.2%), oxacillin (84.2%), gentamicin (76.3%) and cefoperazone (70.3%) were the more effective drugs. High resistance of isolates were found to penicillin (53.5%), ampicillin (41.6%) and neomycin (38.6%). Multiple drug resistance to three or more drugs was observed in 40 (39.6%) isolates. Media of somatic cell count encountered in animals with mastitis and controls were 175,742.67cs/mL and 58,227.6 cs/mL, respectively. Antimicrobials residues in milk were detected in four (2.7%) animals. The present findings showed the low somatic cell count of animals, indicative of good quality of milk. However, pointed the need of control measures for contagious pathogens of bovine mastitis and more attention for prohibition of antimicrobial use in organic dairy farms.

Nos últimos anos cresce a preocupação dos consumidores quanto à qualidade do leite e às condições de produção e bem-estar dos animais. Simultaneamente, aumenta o interesse e o consumo de produtos e subprodutos de origem animal produzidos no sistema orgânico, com destaque para o leite e derivados. O presente estudo investigou a presença de microrganismos patogênicos, a sensibilidade e a multi-resistência dos isolados aos antimicrobianos, a celularidade e a presença de resíduos de drogas no leite de vacas, com e sem mastite, produzido no sistema orgânico. Foram amostradas 148 vacas no período médio de lactação, das quais duas com mastite clínica, 72 com mastite subclínica e 74 sem mastite (controles), provenientes de quatro pequenas propriedades do interior do Estado de São Paulo, certificadas como orgânicas. Staphylococcusaureus (25,7%), Streptococcus spp. (21,4%), Corynebacterium bovis (12,9%), Streptococcus agalactiae (4,3%) e Staphylococcus spp. (4,3%) foram os microrganismos mais frequentemente isolados nos animais com mastite. Aspergillus spp. foi isolado de um animal. Ceftiofur (95,2%), oxacilina (84,2%), gentamicina (76,3%) e cefoperazona (70,3%) foram os antimicrobianos mais efetivos frente aos isolados. As maiores taxas de resistência das linhagens foram constatadas para penicilina (53,5%), ampicilina (41,6%) e neomicina (38,6%). Multi-resistência a três ou mais fármacos foi encontrada em 40 (39,6%) linhagens. A média da contagem de células somáticas das propriedades para animais com mastite foi 175.742,67 céls/mL, enquanto que para os animais controles foi 58.227,6 céls/mL. A presença de resíduos de antimicrobianos foi observada no leite de quatro (2,7%) animais. Os resultados revelaram baixa celularidade média nos animais, indicativo de boa qualidade do leite. Entretanto, apontam para a necessidade da adoção de medidas de controle para microrganismos contagiosos e maior rigor na proibição do uso de antimicrobianos em fazendas de leite orgânico.

Microrganismos patogênicos, celularidade e resíduos de antimicrobianos no leite bovino produzido no sistema orgânico: [revisão] / Pathogenic microorganisms, somatic cell count and drug residues evaluation in organic bovine milk: [revision]

Nos últimos anos cresce a preocupação dos consumidores quanto à qualidade do leite e às condições de produção e bem-estar dos animais. Simultaneamente, aumenta o interesse e o consumo de produtos e subprodutosde origem animal produzidos no sistema orgânico, com destaque para o leite e derivados. O presente estudo investigoua presença de microrganismos patogênicos, a sensibilidade e a multi-resistência dos isolados aos antimicrobianos, a celularidade e a presença de resíduos de drogas no leite de vacas, com e sem mastite, produzido no sistema orgânico. Foram amostradas 148 vacas no período médio de lactação, das quais duas com mastite clínica, 72 com mastite subclínica e 74 sem mastite (controles), provenientes de quatro pequenas propriedades do interior do Estado de São Paulo, certificadas como orgânicas. Staphylococcus aureus (25,7%), Streptococcus spp. (21,4%), Corynebacterium bovis (12,9%), Streptococcus agalactiae (4,3%) e Staphylococcus spp. (4,3%) foram os microrganismos mais frequentemente isolados nos animais com mastite. Aspergillus spp. foi isolado de um animal. Ceftiofur (95,2%), oxacilina (84,2%), gentamicina (76,3%) e cefoperazona (70,3%) foram os antimicrobianos mais efetivos frenteaos isolados. As maiores taxas de resistência das linhagens foram constatadas para penicilina (53,5%), ampicilina (41,6%) e neomicina (38,6%). Multi-resistência a trêsou mais fármacos foi encontrada em 40 (39,6%) linhagens. A média da contagem de células somáticas das propriedades para animais com mastite foi 175.742,67 céls/mL, enquantoque para os animais controles foi 58.227,6 céls/mL. A presença de resíduos de antimicrobianos foi observada no leite de quatro (2,7%) animais. Os resultados revelarambaixa celularidade média nos animais, indicativo de boa qualidade do leite. Entretanto, apontam para a necessidadeda adoção de medidas de controle para microrganismos contagiosos e maior...

In last years increase the importance of milk quality and conditions of bovine milking. Simultaneously, increase the interest about organic milk and derivates. The aim of present study was investigate the milk pathogens, sensitivity and multiple drug resistance of isolates, somatic cell count and residues of drugs in milk, from cattle with and without mastitis, come from four little organic dairy farms in State of São Paulo, Brazil. Were used 148 cattle on the middle period of lactation. From these, two showed clinical mastitis, 72 subclinical mastitis and 74 without signs of mammary inflammation (controls). Staphylococcus aureus (25.7%), Streptococcus spp. (21.4%), Corynebacterium bovis (12.9%), Streptococcus agalactiae (4.3%) and Staphylococcus spp. (4.3%) were the more-frequent microorganismsisolated from animals with mastitis. Aspergillus spp. was isolated from one animal. Ceftiofur (95.2%), oxacillin (84.2%), gentamicin (76.3%) and cefoperazone (70.3%) were the moreeffective drugs. High resistance of isolates were found to penicillin (53.5%), ampicillin (41.6%) and neomycin (38.6%). Multiple drug resistance to three or more drugs was observed in 40 (39.6%) isolates. Media of somatic cell count encountered in animals with mastitis and controls were 175,742.67cs/mL and 58,227.6 cs/mL, respectively. Antimicrobials residuesin milk were detected in four (2.7%) animals. The present findings showed the low somatic cell count of animals, indicative of good quality of milk. However, pointed the need of control measures for contagious pathogens of bovine mastitis and more attention forprohibition of antimicrobial use in organic dairy farms.

Pseudomonas aeruginosa: freqüência de resistência a múltiplos fármacos e resistência cruzada entre antimicrobianos no Recife/PE / Pseudomonas aeruginosa: frequency of resistance to multiple drugs and cross-resistance between antimicrobials in Recife/PE

JUSTIFICATIVA E OBJETIVOS: A multi-resistência bacteriana tem crescido significativamente nos últimos anos. Entre os gram-negativos a P. aeruginosa demonstra maior facilidade de desenvolvimento de resistência aos antibióticos. O objetivo deste estudo foi determinar os padrões de susceptibilidade antimicrobiana, freqüência de resistência a múltiplos fármacos e de resistência cruzada entre antimicrobianos das cepas de Pseudomonas aeruginosa. MÉTODO: O estudo foi realizado entre setembro de 2004 e janeiro de 2006. Os testes de susceptibilidade antimicrobiana foram realizados em 304 cepas de P. aeruginosa segundo os padrões do National Committee for Clinical and Laboratory Standards (NCCLS). RESULTADOS: Os materiais mais freqüentes foram urina com 26,7 por cento e secreção traqueal com 26,1 por cento. Os seguintes antibióticos, com respectivos percentuais de susceptibilidade, foram observados: piperacilina-tazobactam (66,2 por cento); aztreonam (59,8 por cento); amicacina (59,4 por cento); meropenem (58,2 por cento); imipenem (57,7 por cento); ciprofloxacina (49,7 por cento); gentamicina e cefepima (48,6 por cento); ceftazidima (30 por cento) e cefotaxima (6,8 por cento). Detectou-se elevada prevalência de multi-resistência, com 49,7 por cento das cepas resistentes a três antibióticos ou mais e 28 por cento resistentes a seis antibióticos ou mais. Adicionalmente se demonstraram taxas de resistência cruzada entre os beta-lactâmicos (carbapenêmicos e piperacilina/tazobactam) e os aminoglicosídeos e quinolonas entre 22,9 por cento e 38,1 por cento (fármacos comumente utilizados como adjuvantes no tratamento das infecções graves por pseudomonas), refletindo dificuldade nas opções de associação de antimicrobianos para tratamentos combinados. CONCLUSÕES: A freqüência de cepas multi-resistentes de P. aeruginosa foi semelhante à descrita na literatura nacional e maior do que a mundial. Para reduzir a freqüência destes clones multi-resistentes, monitorização...

BACKGROUND AND OBJECTIVES: The frequency of multiple-antibiotic resistant bacteria has been increasing in recent years. Among the gram-negative bacteria Pseudomonas aeruginosa (P. aeruginosa) shows a great propensity for the development of multidrug resistance mechanisms. The objective of this study was to identify the profile of susceptibility to antibiotics, the frequency of multidrug resistance and the cross-resistance between drugs of P. aeruginosa strains in two tertiary hospitals in Recife, Pernambuco. METHODS: The study was carried out between September 2004 and January 2006. The antimicrobial susceptibility testing was performed in 304 strains of P. aeruginosa by the disc diffusion method in accordance with National Committee for Clinical and Laboratory Standards (NCCLS) guidelines. RESULTS: The most frequent materials were urine (26.7 percent) and respiratory tract secretion (26.1 percent) The antibiotics tested and their respective susceptibilities were as follows: piperacillin-tazobactam (66.2 percent); aztreonam (59.8 percent); amikacin (59.4 percent); meropenem (58.2 percent); imipenem (57.7 percent); ciprofloxacin (49.7 percent); gentamicin and cefepime (48.6 percent); ceftazidime (30 percent) and cefotaxime (6.8 percent). A high prevalence of multi-resistance was detected. Half (49.7 percent) the strains showed resistance to three or more antibiotics and 28 percent were resistant to six antimicrobials or more. Also, cross-resistance between the beta-lactams (carbapenems and piperacilin/tazobactam) and aminoglicosides and quinolones was between 22.9 percent and 38.1 percent. These drugs are commonly combined in the treatment of severe infections caused by Pseudomonas, which reflects the difficulty in choosing the appropriate option for combination therapy. CONCLUSIONS: The frequency of multidrug-resistant strains of P. aeruginosa in this study was similar to other hospitals in Brazil and higher than in other countries. In...